Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.
byBenzinga Newsdesk
July 21, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cboe Global Markets Announces Leadership Transition; Fredric J. Tomczyk Named CEO; Edward T. Tilly Resigns As Chairman And CEO; William M. Farrow, III Named Non-Executive Chairman Of The Board Of Directors

By Benzinga Newsdesk
September 19, 8:17 AM
Fredric J. Tomczyk, current member of Cboe Global Markets Board of Directors, and former President and Chief Executive Officer of TD Ameritrade Holding Corporation, named CEOEdward T. Tilly resigns as Chairman and CEO of

CBOE